1.A case of hepatoblastoma misdiagnosed as combined hepatocellular carcinoma and cholangiocarcinoma in an adult.
Keun Woo PARK ; Chang Jin SEO ; Dae Young YUN ; Min Keun KIM ; Byung Seok KIM ; Young Seok HAN ; Hoon Kyu OH ; Chang Hyeong LEE
Clinical and Molecular Hepatology 2015;21(3):300-308
Hepatoblastoma usually occurs in children under the age of 2 years, with very few cases reported in adults. We experienced a case of adult hepatoblastoma in a 36-year-old female with chronic hepatitis B . She had experienced sudden onset abdominal pain. Her serum alpha-fetoprotein level was markedly elevated, and abdominal CT showed a 9-cm mass with internal hemorrhage in the right hepatic lobe with hemoperitoneum, so an emergency hepatic central bisectionectomy was performed. The initial histologic examination revealed that the mass mimicked combined hepatocellular carcinoma and cholangiocarcinoma with spindle-cell metaplasia of the cholangiocarcinoma element. Follow-up abdominal CT performed 3 months later showed a 5.5-cm metastatic mass in the left subphrenic area. Laparoscopic splenectomy with mass excision was performed, and hepatoblastoma was confirmed histologically. A histologic re-examination of previously obtained surgical specimens also confirmed the presence of hepatoblastoma. Metastatic hepatoblastoma was found at multiple sites of the abdomen during follow-up, and so chemotherapy with cisplatin, 5-fluorouracil (5-FU), and vincristine was applied, followed by carboplatin and doxorubicin . Despite surgery and postoperative chemotherapy, she died 12 months after symptom onset.
Adult
;
Carcinoma, Hepatocellular/pathology
;
Cholangiocarcinoma/pathology
;
Cisplatin/therapeutic use
;
Diagnostic Errors
;
Doxorubicin/therapeutic use
;
Drug Therapy, Combination
;
Female
;
Fluorouracil/therapeutic use
;
Hepatitis B, Chronic/complications/diagnosis
;
Hepatoblastoma/drug therapy/*pathology/radiography
;
Humans
;
Liver Neoplasms/drug therapy/*pathology/radiography
;
Tomography, X-Ray Computed
;
Vincristine/therapeutic use
2.Clinical outcomes of systemic chemotherapy in hepatocellular carcinoma patients with multiple lung metastases.
Ki Tae YOON ; Jong Won CHOI ; Jun Yong PARK ; Sang Hoon AHN ; Yong Han PAIK ; Kwan Sik LEE ; Kwang Hyub HAN ; Chae Yoon CHON ; Do Young KIM
The Korean Journal of Hepatology 2008;14(3):360-370
BACKGROUND/AIMS: Advanced hepatocellular carcinoma (HCC) with multiple lung metastases has a poor prognosis with no effective treatment having been established. This study evaluated the outcomes of systemic chemotherapy for advanced HCC with multiple lung metastases. METHODS: Between January 2000 and December 2006, 68 patients were diagnosed with HCC presenting with multiple lung metastases. Sixteen patients in the terminal stage, such as Child-Pugh grade `C' or an Eastern Cooperative Oncology Group performance status exceeding grade 2, were excluded from the analysis. The following treatment modalities were applied: 26 patients received primary tumor treatment (transarterial chemoembolization or intra-arterial chemotherapy) with systemic chemotherapy, 10 patients received primary treatment only, 8 patients received systemic chemotherapy only, and 8 patients received highly supportive care. The treatment responses and median survival times for the modalities were analyzed and compared. RESULTS: The median age of the 52 analyzed patients (45 males) was 52.4 years. The most common etiology of HCC was chronic hepatitis B virus infection (n=44, 84.6%) followed by hepatitis C virus infection (n=2, 3.8%), with the etiology being unknown in 6 cases (11.5%). The treatment modality had no significant effect on the treatment response rate (P=0.432) or median survival time (133, 66, 74, and 96 days for primary tumor treatment with systemic chemotherapy, primary tumor treatment only, systemic chemotherapy only, and highly supportive care, respectively; P=0.067). CONCLUSIONS: We found that systemic chemotherapy was not effective in treating HCC presenting with multiple lung metastases. Improving the effectiveness of systemic treatment and selecting patients who would benefit from such treatment remains a major challenge.
Adult
;
Carcinoma, Hepatocellular/*drug therapy/radiography/*secondary
;
Chemoembolization, Therapeutic
;
Combined Modality Therapy
;
Data Interpretation, Statistical
;
Female
;
Humans
;
Liver Neoplasms/*drug therapy/pathology/radiography
;
Lung Neoplasms/radiography/*secondary
;
Male
;
Middle Aged
;
Neoplasm Staging
;
Retrospective Studies
;
Severity of Illness Index
;
Survival Analysis
;
Treatment Outcome
3.Right Hepatectomy in a Patient with Hepatocellular Carcinoma after Induction of Hepatic Parenchymal Atrophy through Subsequent Portal and Hepatic Vein Embolizations.
The Korean Journal of Gastroenterology 2011;58(3):162-165
No abstract available.
Antineoplastic Agents/administration & dosage
;
Antiviral Agents/therapeutic use
;
Atrophy/pathology
;
Carcinoma, Hepatocellular/pathology/radiography/*therapy
;
*Chemoembolization, Therapeutic
;
Hepatectomy
;
*Hepatic Veins
;
Hepatitis B, Chronic/complications/diagnosis/drug therapy
;
Humans
;
Liver Neoplasms/pathology/radiography/*therapy
;
Male
;
Middle Aged
;
*Portal Vein
;
Tomography, X-Ray Computed
4.Growth rate of early-stage hepatocellular carcinoma in patients with chronic liver disease.
Chansik AN ; Youn Ah CHOI ; Dongil CHOI ; Yong Han PAIK ; Sang Hoon AHN ; Myeong Jin KIM ; Seung Woon PAIK ; Kwang Hyub HAN ; Mi Suk PARK
Clinical and Molecular Hepatology 2015;21(3):279-286
BACKGROUND/AIMS: The goal of this study was to estimate the growth rate of hepatocellular carcinoma (HCC) and identify the host factors that significantly affect this rate. METHODS: Patients with early-stage HCC (n=175) who underwent two or more serial dynamic imaging studies without any anticancer treatment at two tertiary care hospitals in Korea were identified. For each patient, the tumor volume doubling time (TVDT) of HCC was calculated by comparing tumor volumes between serial imaging studies. Clinical and laboratory data were obtained from the medical records of the patients. RESULTS: The median TVDT was 85.7 days, with a range of 11 to 851.2 days. Multiple linear regression revealed that the initial tumor diameter (a tumor factor) and the etiology of chronic liver disease (a host factor) were significantly associated with the TVDT. The TVDT was shorter when the initial tumor diameter was smaller, and was shorter in HCC related to hepatitis B virus (HBV) infection than in HCC related to hepatitis C virus (HCV) infection (median, 76.8 days vs. 137.2 days; P=0.0234). CONCLUSIONS: The etiology of chronic liver disease is a host factor that may significantly affect the growth rate of early-stage HCC, since HBV-associated HCC grows faster than HCV-associated HCC.
Adult
;
Aged
;
Aged, 80 and over
;
Antiviral Agents/therapeutic use
;
Carcinoma, Hepatocellular/complications/*pathology/radiography
;
Demography
;
Female
;
Hepatitis B, Chronic/*complications/drug therapy
;
Hepatitis C, Chronic/*complications/drug therapy
;
Humans
;
Linear Models
;
Liver Neoplasms/complications/*pathology/radiography
;
Magnetic Resonance Imaging
;
Male
;
Middle Aged
;
Neoplasm Staging
;
Republic of Korea
;
Retrospective Studies
;
Tertiary Care Centers
;
Tomography, X-Ray Computed
5.Combination treatment with intrahepatic arterial infusion and intratumoral injection chemotherapy in patients with far-advanced hepatocellular carcinoma and arterioportal or arteriovenous shunts: preliminary results.
Ja Seon KIM ; Young Min PARK ; Nha Young KIM ; Han Kyeol YUN ; Ki Jong LEE ; Bo Hyun KIM ; Sang Jong PARK ; Jae Woo YEON ; Guhung JUNG
The Korean Journal of Hepatology 2011;17(2):120-129
BACKGROUND/AIMS: Combination treatment consisting of hepatic arterial infusion chemotherapy with epirubicin and cisplatin (HAIC-EC) and systemic infusion of low-dose 5-fluorouracil (5-FU) are sometimes effective against advanced hepatocellular carcinoma (HCC). However, there is no effective treatment for advanced HCCs with arterioportal shunts (APS) or arteriovenous shunts (AVS). METHODS: We investigated a response and adverse events of a new combination protocol of repeated HAIC-EC and percutaneous intratumoral injection chemotherapy with a mixture of recombinant interferon-gamma (IFN-gamma) and 5-FU (PIC-IF) in patients with far-advanced HCCs with large APSs or AVSs. RESULTS: There was a complete response (CR) for the large vascular shunts in all three patients and for all tumor burdens in two patients. Significant side effects were flu-like symptoms (grade 2) and bone marrow suppression (grade 2 or 3) after each cycle, but these were well-tolerated. CONCLUSIONS: These results suggest that the combination of HAIC-EC and PIC-IF is a new and promising approach for advanced HCC accompanied by a large APS or AVS.
Aged
;
Angiography
;
Antineoplastic Combined Chemotherapy Protocols/*therapeutic use
;
Carcinoma, Hepatocellular/*drug therapy/pathology/radiography
;
Cisplatin/administration & dosage
;
Epirubicin/administration & dosage
;
Fluorouracil/administration & dosage
;
Hepatic Artery
;
Humans
;
Infusions, Intra-Arterial
;
Injections, Intramuscular
;
Interferon-gamma, Recombinant/administration & dosage
;
Liver Neoplasms/*drug therapy/pathology/radiography
;
Male
;
Tomography, X-Ray Computed
;
Tumor Burden
6.A Simplified Technique of Percutaneous Hepatic Artery Port-Catheter Insertion for the Treatment of Advanced Hepatocellular Carcinoma with Portal Vein Invasion.
Sun Young CHOI ; Ah Hyun KIM ; Kyung Ah KIM ; Jong Yun WON ; Do Yun LEE ; Kwang Hun LEE
Korean Journal of Radiology 2010;11(6):648-655
OBJECTIVE: We assessed the outcomes of a simplified technique for the percutaneous placement of a hepatic artery port-catheter system for chemotherapy infusion in advanced hepatocellular carcinoma with portal vein invasion. MATERIALS AND METHODS: From February 2003 to February 2008, percutaneous hepatic artery port-catheter insertion was performed in 122 patients who had hepatocellular carcinoma with portal vein invasion. The arterial access route was the common femoral artery. The tip of the catheter was wedged into the right gastroepiploic artery without an additional fixation device. A side hole was positioned at the distal common hepatic artery to allow the delivery of chemotherapeutic agents into the hepatic arteries. Coil embolization was performed only to redistribute to the hepatic arteries or to prevent the inadvertent delivery of chemotherapeutic agents into extrahepatic arteries. The port chamber was created at either the supra-inguinal or infra-inguinal region. RESULTS: Technical success was achieved in all patients. Proper positioning of the side hole was checked before each scheduled chemotherapy session by port angiography. Catheter-related complications occurred in 19 patients (16%). Revision was achieved in 15 of 18 patients (83%). CONCLUSION: This simplified method demonstrates excellent technical feasibility, an acceptable range of complications, and is hence recommended for the management of advanced hepatocellular carcinoma with portal vein thrombosis.
Angiography
;
Antineoplastic Agents/*administration & dosage
;
Carcinoma, Hepatocellular/*drug therapy/pathology
;
*Catheters, Indwelling/adverse effects
;
Embolization, Therapeutic
;
Female
;
Femoral Artery/surgery
;
Fluoroscopy
;
*Hepatic Artery
;
Humans
;
Infusions, Intra-Arterial
;
Liver Neoplasms/*drug therapy/pathology
;
Male
;
Middle Aged
;
Portal Vein/*pathology
;
*Radiography, Interventional
;
Treatment Outcome
7.Spinal cord injury after conducting transcatheter arterial chemoembolization for costal metastasis of hepatocellular carcinoma.
Sang Jung PARK ; Chang Ha KIM ; Jin Dong KIM ; Soon Ho UM ; Sun Young YIM ; Min Ho SEO ; Dae In LEE ; Jun Hyuk KANG ; Bora KEUM ; Yong Sik KIM
Clinical and Molecular Hepatology 2012;18(3):316-320
Transcatheter arterial chemoembolization (TACE) has been used widely to treat patients with unresectable hepatocellular carcinoma. However, this method can induce various adverse events caused by necrosis of the tumor itself or damage to nontumor tissues. In particular, neurologic side effects such as cerebral infarction and paraplegia, although rare, may cause severe sequelae and permanent disability. Detailed information regarding the treatment process and prognosis associated with this procedure is not yet available. We experienced a case of paraplegia that occurred after conducting TACE through the intercostal artery to treat hepatocellular carcinoma that had metastasized to the rib. In this case, TACE was attempted to relieve severe bone pain, which had persisted even after palliative radiotherapy. A sudden impairment of sensory and motor functions after TACE developed in the trunk below the level of the sternum and in both lower extremities. The patient subsequently received steroid pulse therapy along with supportive care and continuous rehabilitation. At the time of discharge the patient had recovered sufficiently to enable him to walk by himself, although some paresthesia and spasticity remained.
Antiviral Agents/therapeutic use
;
Bone Neoplasms/radiography/secondary
;
Carcinoma, Hepatocellular/diagnosis/pathology/*therapy
;
Catheter Ablation
;
Chemoembolization, Therapeutic/*adverse effects
;
Hepatitis B/complications/drug therapy
;
Humans
;
Liver Cirrhosis/etiology
;
Liver Neoplasms/diagnosis/pathology/*therapy
;
Male
;
Middle Aged
;
Positron-Emission Tomography
;
Soft Tissue Neoplasms/secondary
;
Spinal Cord Injuries/*etiology
;
Tomography, X-Ray Computed
8.A Case of Epidural Abscess Occurred after Liver Abscess Complicated by Transarterial Chemoembolization in a Patient with Metastatic Cancer to Liver.
Yong Jae LEE ; Gwang Ha KIM ; Do Youn PARK ; Suk KIM ; Chang Jun PARK ; Tae Kyun KIM ; Jung Hee KOH
The Korean Journal of Gastroenterology 2013;61(4):225-229
Transarterial chemoembolization (TACE) is one of the most effective therapies for unresectable hepatocelluar carcinoma or metastatic hypervascular tumors. Abscess occurring in the other organs beside the liver after TACE is a complication that often occurs, sometimes potentially fatal. We report a case of spinal epidural abscess occurred after liver abscess complicated by TACE in a patient with metastatic neuroendocrine tumors to the liver. A 67-year-old female underwent TACE first for the metastatic lesions to liver, with a history of pancreatoduodenectomy for the primary pancreatic neuroendocrine tumor. Four days after TACE, sudden high fever occurred, and liver abscess was found on abdominal CT. Two days later, back pain and radiating pain to the right leg occurred, and lumbar spine MRI showed spinal epidural abscess. After intravenous antibiotics for 8 weeks and partial laminectomy, the patient recovered and was discharged without complications.
Aged
;
Anti-Bacterial Agents/therapeutic use
;
Carcinoma, Hepatocellular/secondary/*therapy
;
Chemoembolization, Therapeutic/*adverse effects
;
Epidural Abscess/*etiology/microbiology/surgery
;
Escherichia coli/isolation & purification
;
Escherichia coli Infections/drug therapy
;
Female
;
Humans
;
Laminectomy
;
Liver Abscess/*etiology
;
Liver Neoplasms/secondary/*therapy
;
Lumbar Vertebrae/microbiology/radiography
;
Magnetic Resonance Imaging
;
Neuroendocrine Tumors/pathology/surgery
;
Pancreaticoduodenectomy
;
Tomography, X-Ray Computed